The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
1. Specific Aim: To show the safety and efficacy of prolotherapy injection for chronic
sacroiliac and myofascial lumbar pain while standardizing an ultrasound guided injection
technique
2. Specific Aim: To demonstrate that dextrose prolotherapy subjectively decreases lumbar
back pain (LBP) associated with chronic sacroiliac (SI) and myofascial lumbar back
pain/injury in patients with Hypermobile-Type Ehlers-Danlos Syndrome (hEDS).
3. Specific Aim: To use ultrasound (US) guidance to identify SI and myofascial lumbar back
pain/injury for targeted dextrose prolotherapy treatment and to provide objective
measures of decreasing inflammation via Power Doppler and ligament repair.
4. Specific Aim: To determine if US-guided dextrose prolotherapy decreases the direct costs
of care for chronic LBP in contrast to conventional therapies by reducing return visits,
specialty referrals, physical therapy, medications, and unnecessary procedures.